What Is the Evidence on Immunomodulators and Immunosuppressants for Progressive Multiple Sclerosis? - A Cochrane Review Summary with Commentary., PMID:40485316
A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS)., PMID:40465056
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study., PMID:40451284
Disease Course in Patients Switched from Natalizumab to Alemtuzumab: An Italian Multicenter, Prospective, Observational Study., PMID:40397068
Comparative Efficacy and Safety of Extended Versus Standard Interval Dosing of Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients: A Multicenter Analysis., PMID:40387571
Long-term safety evaluation of natalizumab during pregnancy and lactation in patients with multiple sclerosis., PMID:40332701
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells., PMID:40277931
Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy., PMID:40220155
Pyoderma gangrenosum in a patient with multiple sclerosis under natalizumab treatment: a case report., PMID:40175973
Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis., PMID:40163140
No evidence of fluctuations in daily step count between infusions in people with multiple sclerosis treated with anti-CD20 monoclonal antibodies., PMID:40144903
Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura., PMID:40134425
Rituximab for people with multiple sclerosis., PMID:40066932
[Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis]., PMID:40047834
Successful Natalizumab Treatment of Two Female Individuals With Susac Syndrome., PMID:40028847
Is it time to consider the live attenuated varicella-zoster virus (VZV) vaccination safe in patients with multiple sclerosis treated with natalizumab? An extension study of the first Iranian experience., PMID:39970866
Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis., PMID:39960455
De-Escalation of Disease-Modifying Therapy in Multiple Sclerosis-A Danish Nationwide Cohort Study., PMID:39895213
Effectiveness of 6-week dosing of Natalizumab versus continued 4-week treatment for Multiple Sclerosis: An observational registry-based study., PMID:39893751
Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: A real-world, multi-center, propensity score-matched study., PMID:39880749
Analysis of serum natalizumab concentrations obtained during routine clinical care in patients with multiple sclerosis: A cross-sectional study., PMID:39879941
Effectiveness of Ocrelizumab on Disease Progression and Disability Status in Multiple Sclerosis Patients: A Two-Year Prospective Cohort Study., PMID:39860559
Effect of Different Treatments on Retinal Thickness Changes in Patients With Multiple Sclerosis: A Review., PMID:39853938
Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study., PMID:39821478
Cost effectiveness of different treatment strategies with natalizumab for pregnant women with multiple sclerosis., PMID:39776288
Analysis of Immunological Memory for John Cunningham Virus in a Mexican Population of Patients with Multiple Sclerosis Under Treatment., PMID:39767644
Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments., PMID:39755026
Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile., PMID:39749348
Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials., PMID:39711787
Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcome., PMID:39686558
Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients., PMID:39684862
Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of patients with multiple sclerosis: a systematic review and meta-analysis., PMID:39673046
Anti-JCV antibody index seroconversion in Turkish multiple sclerosis patients treated with natalizumab., PMID:39671016
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab., PMID:39582359
Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice., PMID:39579054
Improvement of fatigue, depression, and processing speed two weeks post Natalizumab infusion in Multiple Sclerosis: No difference between standard and extended interval dosing schedules., PMID:39504729
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients., PMID:39494701
Identification of alemtuzumab-suitable multiple sclerosis patients in Slovakia and sequencing of post-alemtuzumab immunomodulatory treatment., PMID:39494112
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies., PMID:39442037
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis., PMID:39393045
Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis., PMID:39373183
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab., PMID:39343860
Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study., PMID:39264442
A 2-stage model of heterogenous treatment effects for brain atrophy in multiple sclerosis utilizing the MS PATHS research network., PMID:39260226
Enhanced and cross-reactive in vitro memory B cell response against Epstein-Barr virus nuclear antigen 1 in multiple sclerosis., PMID:39257578
Patient and Physician Perspectives on the Wearing-Off Effect in Multiple Sclerosis: Results From Structured Interviews (P1-6.015)., PMID:39255432
Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis., PMID:39254048
Comparative efficacy of subcutaneous versus intravenous natalizumab on annualized relapse rate: A post-hoc analysis of the REFINE study., PMID:39226723
Global Hyperperfusion in the Brain at Onset of the Immune Reconstitution Inflammatory Syndrome in a Patient With Natalizumab-Associated PML., PMID:39213467
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod., PMID:39177751
For research use only. Not for human or drug use.
